![](/img/cover-not-exists.png)
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)
Penrose, Kerri J., Parikh, Urvi M., Hamanishi, Kristen A., Else, Laura, Back, David, Boffito, Marta, Jackson, Akil, Mellors, John W.Language:
english
Journal:
Journal of Infectious Diseases
DOI:
10.1093/infdis/jiv528
Date:
November, 2015
File:
PDF, 868 KB
english, 2015